Tyra Biosciences Inc
NASDAQ:TYRA

  • LAST PRICE
    16.1300
  • TODAY'S CHANGE (%)
    0.0200 (0.1241%)
  • Bid / Lots
    16.1100/ 1
  • Ask / Lots
    16.1600/ 6
  • Open / Previous Close
    16.0200 / 16.1100
  • Day Range
    15.6000
    16.5000
  • 52 Week Range
    10.6004
    29.6000
  • Volume
    88,034

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
      Companies Mentioned: TYRA

      Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -

      IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) -

      Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer -

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: TYRA
      September 30, September 30, ------------------------ ------------------------ 2024 2023 2024 2023 ----------- ----------- ----------- ----------- Operating expenses: Research and development $ 22,697 $ 19,271 $ 57,897 $ 41,841 General and administrative 5,907 4,692 16,536 12,470 ---------- ---------- ---------- ---------- Total operating expenses 28,604 23,963 74,433 54,311 ---------- ---------- ---------- ---------- Loss from operations (28,604) (23,963) (74,433) (54,311) Other income: Interest and other income, net 4,588 2,811 13,523 8,007 ---------- ---------- ---------- ---------- Total other income 4,588 2,811 13,523 8,007 ---------- ---------- ---------- ---------- Net loss (24,016) (21,152) (60,910) (46,304) ---------- ---------- ---------- ---------- Unrealized gain on marketable securities available-for-sale, net 1,936 -- 1,371 -- ---------- ---------- ---------- ---------- Comprehensive loss $ (22,080) $ (21,152) $ (59,539) $ (46,304) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.41) $ (0.49) $ (1.08) $ (1.09) Weighted-average shares used to compute net loss per share, basic and diluted 58,874,497 42,868,340 56,599,050 42,619,075

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: TYRA
      September 30, September 30, ------------------------ ------------------------ 2024 2023 2024 2023 ----------- ----------- ----------- ----------- Operating expenses: Research and development $ 22,697 $ 19,271 $ 57,897 $ 41,841 General and administrative 5,907 4,692 16,536 12,470 ---------- ---------- ---------- ---------- Total operating expenses 28,604 23,963 74,433 54,311 ---------- ---------- ---------- ---------- Loss from operations (28,604) (23,963) (74,433) (54,311) Other income: Interest and other income, net 4,588 2,811 13,523 8,007 ---------- ---------- ---------- ---------- Total other income 4,588 2,811 13,523 8,007 ---------- ---------- ---------- ---------- Net loss (24,016) (21,152) (60,910) (46,304) ---------- ---------- ---------- ---------- Unrealized gain on marketable securities available-for-sale, net 1,936 -- 1,371 -- ---------- ---------- ---------- ---------- Comprehensive loss $ (22,080) $ (21,152) $ (59,539) $ (46,304) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.41) $ (0.49) $ (1.08) $ (1.09) Weighted-average shares used to compute net loss per share, basic and diluted 58,874,497 42,868,340 56,599,050 42,619,075

  • Oct 29, 2024

Peers Headlines